Talidox better than caelyx/doxil and free doxorubicin
In the in vivo study of the Mario Negri Institute, the effect of different treatments on tumor size in mice was examined, whereby in addition to an untreated control group (black) our product Talidox (turquoise) was compared with the therapies currently used in clinics, free doxorubicin (gray) and Caelyx/Doxil (red) . Over a period of three weeks, the groups were treated with total of six injections of identical doses of active ingredient. Compared to the two products Caelyx/Doxil and free Doxorubicin that are already approved in the market, treatment with Talidox causes a significantly reduced tumor growth. Compared to treatment with Caelyx/Doxil, Talidox could reduce the average tumor growth by 29% – compared with free doxorubicin even by 42%.